Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 2
2005 1
2006 3
2009 2
2010 1
2013 4
2014 1
2015 7
2016 8
2017 6
2018 7
2019 3
2020 5
2021 7
2022 8
2023 15
2024 12
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Perianal Fistulizing Crohn's Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care.
Hanna LN, Anandabaskaran S, Iqbal N, Geldof J, LeBlanc JF, Dige A, Lundby L, Vermeire S, D'Hoore A, Verstockt B, Bislenghi G, De Looze D, Lobaton T, Van de Putte D, Spinelli A, Carvello M, Danese S, Buskens CJ, Gecse K, Hompes R, Becker M, van der Bilt J, Bemelman W, Sebastian S, Moran G, Lightner AL, Wong SY, Colombel JF, Cohen BL, Holubar SD, Ding NS, Behrenbruch C, Sahnan K, Misra R, Lung P, Hart A, Tozer P. Hanna LN, et al. Among authors: ding ns. Clin Gastroenterol Hepatol. 2025 May;23(6):914-926. doi: 10.1016/j.cgh.2024.06.047. Epub 2024 Aug 10. Clin Gastroenterol Hepatol. 2025. PMID: 39134293 Free article. Review.
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P. Choy MC, et al. Among authors: ding ns. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):981-996. doi: 10.1016/S2468-1253(24)00200-0. Epub 2024 Sep 2. Lancet Gastroenterol Hepatol. 2024. PMID: 39236736 Clinical Trial.
Management of inflammatory bowel disease.
Wright EK, Ding NS, Niewiadomski O. Wright EK, et al. Among authors: ding ns. Med J Aust. 2018 Sep 1;209(7):318-323. doi: 10.5694/mja17.01001. Med J Aust. 2018. PMID: 30257634 Review.
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
Schulberg JD, Wright EK, Holt BA, Hamilton AL, Sutherland TR, Ross AL, Vogrin S, Miller AM, Connell WC, Lust M, Ding NS, Moore GT, Bell SJ, Shelton E, Christensen B, De Cruz P, Rong YJ, Kamm MA. Schulberg JD, et al. Among authors: ding ns. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):318-331. doi: 10.1016/S2468-1253(21)00393-9. Epub 2021 Dec 8. Lancet Gastroenterol Hepatol. 2022. PMID: 34890567 Clinical Trial.
Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC.
Li Wai Suen CFD, Choy MC, Con D, Cheng K, Nigro J, Breheney K, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith GL, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, Grosserichter-Wagener C, Te Velthuis H, Visvanathan K, De Cruz P. Li Wai Suen CFD, et al. Among authors: ding ns. Gastroenterology. 2025 Jul 21:S0016-5085(25)05777-4. doi: 10.1053/j.gastro.2025.07.020. Online ahead of print. Gastroenterology. 2025. PMID: 40701396
88 results